Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan [2]

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 2, 2005, Pages 276-278

  Bell, Jan M ^a   Turnidge, John D ^a   Inoue, Matsuhisa ^b   Kohno, Shigeru ^c   Hirakata, Yoichi ^c   Ono, Yasuo ^d   Jones, Ronald N ^e  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JMI LABORATORIES   (United States)

Author keywords

In vitro activity; MDR; Novel antimicrobial

Indexed keywords

CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; OXACILLIN; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DILUTION; DRUG POTENCY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; JAPAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

AMIDOHYDROLASES; DRUG RESISTANCE, BACTERIAL; HUMANS; JAPAN; PEPTIDES; PROTEASE INHIBITORS;

EID: 14744299304     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh547     Document Type: Letter

References (11)

1. Apfel, C. M., Locher, H., Evers, S. et al. (2001). Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrobial Agents and Chemotherapy 45, 1058-64.
2. Credito, K., Lin, G., Ednie, L. M. et al. (2004). Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrobial Agents and Chemotherapy 48, 4033-6.
3. Ednie, L. M., Pankuch, G. & Appelbaum, P. C. (2004). Antipneumococcal activity of LBM415, a new peptide diformylase inhibitor, compared with those of other agents. Antimicrobial Agents and Chemotherapy 48, 4027-32.
4. Jones, R. N., Fritsche, T. R. & Sader, H. S. (2004). Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagnostic Microbiology and Infectious Disease 49, 63-5.
5. Jones, R. N., Moet, G. J., Sader, H. S. et al. (2004). Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. Journal of Antimicrobial Chemotherapy 53, 804-7.
6. Bell, J. M. & Turnidge, J. D. (2002). High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrobial Agents and Chemotherapy 46, 879-81.
7. Bell, J. M., Turnidge, J. D. & Jones, R. N. (2002). Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. International Journal of Antimicrobial Agents 19, 125-32.
8. National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA.
9. Hasegawa, K., Chiba, N., Kobayashi, R. et al. (2004). Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrobial Agents and Chemotherapy 48, 1509-14.
10. Gross, M., Clements, J., Beckett, R. P. et al. (2004). Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. Journal of Antimicrobial Chemotherapy 53, 487-93.
11. Lofland, D., Difuntorum, S., Waller, A. et al. (2004). In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. Journal of Antimicrobial Chemotherapy 53, 664-8.